Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells

The main curative treatments for hepatocellular carcinoma (HCC) are surgical resection and liver transplantation, which only benefits 15% to 25% of patients. In addition, HCC is highly refractory and resistant to cytotoxic chemotherapy. Although several multi-kinase inhibitors, such as sorafenib, re...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Pei-Ming, Lin, Li-Shan, Liu, Tsang-Pai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022495/
https://www.ncbi.nlm.nih.gov/pubmed/31936661
http://dx.doi.org/10.3390/biom10010117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7022495/
https://www.ncbi.nlm.nih.gov/pubmed/31936661
http://dx.doi.org/10.3390/biom10010117

Ejemplares similares